Volume 10, Issue 36 (12-2003)                   RJMS 2003, 10(36): 547-552 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Soroush J, Razavi S, Nojoomi M. COMPARING TWO EMPIRIC ANTIBIOTIC REGIMENS IN TREATMENT OF FEBRILE NEUTROPENIC CANCER PATIENTS. RJMS 2003; 10 (36) :547-552
URL: http://rjms.iums.ac.ir/article-1-199-en.html
Abstract:   (8400 Views)
Since patients with hematologic malignancies and some solid tumors have prolonged periods of severe neutropenia due to the disease itself or its intensive chemotherapy, they often develop life-threatening infections which can be controlled by using appropriate empiric antibiotic regimens. The variety and combination of antibiotics is to the extent that a more common one can be replaced by the others. Therefore, this study was conducted to investigate whether a regimen like Piperacillin and Amikacin could be as useful as a routine regimen such as Ceftazidime and Amikacin or not. In a randomized multicenter clinical trial, 73 patients were randomly treated by two different regimens. The first group(37 patients) was treated with Ceftazidime (2gr/TDS/IV) plus Amikacin (15 mgr/kg/IV infusion daily) and the second group (36 patients) with Piperacillin (4gr/q4 hr/IV) plus Amikacin. Becoming afebrile in 48 or 72 hours after beginning antibiotic regimen was the response criterion to treatment. 27 patients(73%) in the first and 23(63.9%) in the second group responded to the treatment. Statistically, there was no significant difference between the responses to treatment in both groups. As a whole, 50 out of 73 patients (68.5%) responded to our initial treatment and the two regimens were statistically & equally effective. So we recommend that the combination of Piperacillin plus Amikacin can also be used as a suitable treatment in febrile neutropenic cancer patients in our country.
Full-Text [PDF 168 kb]   (2980 Downloads)    
Type of Study: Research | Subject: Pharmacology

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Razi Journal of Medical Sciences

Designed & Developed by : Yektaweb